Sheena Jonathan sold $45K of NTRA

Sheena Jonathan sold 112 shares of Natera, Inc. (NTRA) at an average of $399.97 ($388.20–$400.29) across 2 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Nov 5, 2026, 2:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
high confidence
Mentioned
$NTRA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

A small insider sell typically has limited price impact but can trigger short‑term scrutiny.

02

Market read

The filing provides a fresh, albeit minor, data point for traders tracking insider activity.

03

What to watch

The director retains a large stake (over 200k shares), suggesting continued confidence.

Relevance 2/10Novelty 2/10Timing: post‑market filing on 2026‑11‑02

Background

SEC Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$NTRABearishHigh confidence
Context

Director Sheena Jonathan sold 112 shares (~$45K) of Natera via a 10b5‑1 plan, reducing her holdings to 217,574 shares.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

A director offloading shares, even in a small amount, can be interpreted as a weak sell signal, especially when disclosed via a Form 4.

Market effects

Minimal; the sale does not affect the broader genetic‑testing sector.

None; impact confined to Natera shareholders.

Low; no systemic effect.

Counterpoint

The sale may be routine under a pre‑arranged plan and not indicative of future performance.

Key entities

  • Sheena Jonathan

    Director of Natera, Inc.

  • Natera, Inc.

    Genetic testing company listed on NASDAQ under ticker NTRA.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.